Weekly 80 mg adalimumab appears to be an effective and well-tolerated intensification strategy in pediatric CD patients with pharmacokinetic loss of response. Further prospective studies are needed to confirm these findings and guide optimal use.
Building similarity graph...
Analyzing shared references across papers
Loading...
Eyal Cohen‐Sela
Anat Yerushalmy‐Feler
Firas Rinawi
Journal of Pediatric Gastroenterology and Nutrition
Tel Aviv University
Tel Aviv Sourasky Medical Center
Rambam Health Care Campus
Building similarity graph...
Analyzing shared references across papers
Loading...
Cohen‐Sela et al. (Sun,) studied this question.
www.synapsesocial.com/papers/69ba42dc4e9516ffd37a37f8 — DOI: https://doi.org/10.1002/jpn3.70397
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: